Jump To


Last updated on MDtodate: 10/12/2022


Long-acting beta2-adrenergic agonists, such as STRIVERDI RESPIMAT, as monotherapy (without an inhaled corticosteroid) for asthma, increase the risk of asthma-related events. STRIVERDI RESPIMAT is not indicated for the treatment of asthma.

Clinical Trials Experience In Chronic Obstructive Pulmonary Disease

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The STRIVERDI RESPIMAT clinical development program included seven dose-ranging trials and eight confirmatory trials. Four of the confirmatory trials were 6week cross-over trials and four were 48-week parallel group trials. Adverse reactions observed in the dose-ranging trials and four 6-week cross-over trials were consistent with those observed in the 48-week parallel group trials, which formed the primary safety database.

The primary safety database consisted of pooled data from the four 48-week double-blind, active and placebo-controlled, parallel group confirmatory clinical trials. These trials included 3104 adult COPD patients (77% males and 23% females) 40 years of age and older. Of these patients, 876 and 883 patients were treated with STRIVERDI RESPIMAT 5 mcg and 10 mcg once-daily, respectively. The STRIVERDI RESPIMAT groups were composed of mostly Caucasians (66%) with a mean age of 64 years and a mean percent predicted FEV1 at baseline of 44% for both the 5 mcg and 10 mcg treatment groups. Control arms for comparison included placebo in all four trials plus formoterol 12 mcg in two trials.

In these four clinical trials, seventy-two percent (72%) of patients exposed to any dose of STRIVERDI RESPIMAT reported an adverse reaction compared to 71% in the placebo group. The proportion of patients who discontinued due to an adverse reaction was 7.2% for STRIVERDI RESPIMAT treated patients compared to 8.8% for placebo treated patients. The adverse reaction most commonly leading to discontinuation was worsening COPD. The most common serious adverse reactions were COPD exacerbation, pneumonia, and atrial fibrillation.

Table 1 shows all adverse drug reactions reported by at least 2% of patients (and higher than placebo) who received STRIVERDI RESPIMAT 5 mcg during the 48week trials.

Table 1 : Number and frequency of adverse drug reactions greater than 2% (and higher than placebo) in COPD patients exposed to STRIVERDI RESPIMAT 5 mcg: Pooled data from the four 48-week, double-blind, active-and placebo-controlled clinical trials in COPD patients 40 years of age and older


Treatment STRIVERDI 5 mcg once-daily Placebo
Body system (adverse drug reaction) n=876 n (%) n=885 n (%)
Infections and infestations
Nasopharyngitis 99 (11.3) 68 (7.7)
Upper Respiratory Tract Infection 72 (8.2) 66 (7.5)
Bronchitis 41 (4.7) 32 (3.6)
Urinary Tract Infection 22 (2.5) 9 (1.0)
Respiratory, thoracic, and mediastinal disorders
Cough 37 (4.2) 35 (4.0)
Nervous system disorders
Dizziness 20 (2.3) 19 (2.1)
Skin and subcutaneous tissue disorders
Rash* 19 (2.2) 10 (U)
Gastrointestinal disorders
Diarrhea 25 (2.9) 22 (2.5)
Musculoskeletal and connective tissue disorders
Back Pain 31 (3.5) 24 (2.7)
Arthralgia 18 (2.1) 7 (0.8)
*Rash includes a grouping of similar terms


Additional adverse reactions that occurred in greater than 2% (and higher than placebo) of patients exposed to STRIVERDI RESPIMAT 10 mcg were pneumonia, constipation, and pyrexia.

Lung cancers were reported in 6 (0.7%), 3 (0.3%), and 2 (0.2%) patients who received STRIVERDI RESPIMAT 10 mcg, 5 mcg, and placebo, respectively.




Read Next Article

PHP Code Snippets Powered By : XYZScripts.com